Q2 2025 Agios Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Agios Pharmaceuticals Inc (AGIO) reported a 45% increase in net PYRUKYND revenue for the second quarter of 2025 compared to the same period in 2024.
- The company is well-capitalized with approximately $1.3 billion in cash, cash equivalents, and marketable securities, supporting its growth and pipeline development.
- Agios Pharmaceuticals Inc (AGIO) has entered into strategic partnerships with Avanzanite Bioscience and NewBridge Pharmaceuticals to commercialize PYRUKYND in Europe and the GCC, respectively, which are structured as revenue-sharing arrangements.
- The company is on track to potentially launch PYRUKYND for thalassemia in the US, pending FDA approval, with a PDUFA goal date set for September 7, 2025.
- Agios Pharmaceuticals Inc (AGIO) is advancing its pipeline with multiple clinical trials, including the RISE UP Phase III trial for PYRUKYND in sickle cell disease and a Phase IIb trial for tebapivat in myelodysplastic syndromes.
- Agios Pharmaceuticals Inc (AGIO) anticipates quarter-on-quarter variability in net revenues due to ordering patterns and the transition of sales focus to thalassemia.
- The company reported increased R&D expenses, primarily driven by a $10 million milestone payment related to the development of AG-236.
- SG&A expenses increased by $10.4 million compared to the prior year, reflecting continued investment ahead of the potential commercial launch of PYRUKYND for thalassemia.
- Pending approval for thalassemia, Agios Pharmaceuticals Inc (AGIO) expects softer PKD demand as the sales force transitions promotional focus.
- The company does not expect thalassemia revenues to be material in 2025 due to the timing of the PDUFA goal date and the time required to convert patient enrollment forms to treatment initiations.
Good morning, and welcome to Agios second quarter 2025 conference call. (Operator Instructions) Please be advised that this call is being recorded at Agios' request. I would now like to turn the call over to Agios. Please go ahead.
Thank you, operator. Good morning, everyone. I'm [ Morgan Sanford ], Vice President of Investor Relations at Agios. Thank you for joining us to discuss Agios Pharmaceuticals Second Quarter 2025 Financial Results and Business Highlights. You can access the slides for today's call by going to the Investors section of our website, agios.com.
Please move to the next slide.Today, we'll be making certain forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements. Because of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. Next slide, please.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
